Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

BACKGROUND: The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer the best chance of disease control; however, the design of successful combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Louise M. E., Holmes, Matthew, Michael, Joanne L., Scott, Gina B., West, Emma J., Scott, Karen J., Parrish, Christopher, Hall, Kathryn, Stäble, Sina, Jennings, Victoria A., Cullen, Matthew, McConnell, Stewart, Langton, Catherine, Tidswell, Emma L., Shafren, Darren, Samson, Adel, Harrington, Kevin J., Pandha, Hardev, Ralph, Christy, Kelly, Richard J., Cook, Gordon, Melcher, Alan A., Errington-Mais, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604201/
https://www.ncbi.nlm.nih.gov/pubmed/31262361
http://dx.doi.org/10.1186/s40425-019-0632-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604201/
https://www.ncbi.nlm.nih.gov/pubmed/31262361
http://dx.doi.org/10.1186/s40425-019-0632-y

Ejemplares similares